This provides a clearer link between infection dynamics and other pathological aspects of DFUs, such as inflammation and tissue remodeling, emphasizing the potential therapeutic benefits of modulating IL-17 to improve outcomes in DFUs management. This evidence concerns the gene IL17A and infection.